DK1656391T3 - Modificerede humane IGF-1R antistoffer - Google Patents

Modificerede humane IGF-1R antistoffer

Info

Publication number: DK1656391T3
Authority: DK; Denmark
Prior art keywords: antibodies; modified human; human igf; igf; modified
Prior art date: 2003-08-13

Application number

DK04744197.7T

Other languages

English (en)

Inventor

Bruce David Cohen

Vahe Bedian

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-13

Filing date

2004-08-03

Publication date

2011-01-03

2004-08-03 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2011-01-03 Application granted granted Critical

2011-01-03 Publication of DK1656391T3 publication Critical patent/DK1656391T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]

DK04744197.7T 2003-08-13 2004-08-03 Modificerede humane IGF-1R antistoffer DK1656391T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US49520003P	2003-08-13	2003-08-13
PCT/IB2004/002555 WO2005016967A2 (en)	2003-08-13	2004-08-03	Modified human igf-1r antibodies

Publications (1)

Publication Number	Publication Date
DK1656391T3 true DK1656391T3 (da)	2011-01-03

Family

ID=34193291

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04744197.7T DK1656391T3 (da)	2003-08-13	2004-08-03	Modificerede humane IGF-1R antistoffer

Country Status (37)

Country	Link
US (2)	US7371378B2 (da)
EP (1)	EP1656391B1 (da)
JP (1)	JP4638870B2 (da)
KR (1)	KR100825156B1 (da)
CN (1)	CN1835975B (da)
AP (1)	AP2006003510A0 (da)
AR (1)	AR045247A1 (da)
AT (1)	ATE484525T1 (da)
AU (1)	AU2004265152A1 (da)
BR (1)	BRPI0413466A (da)
CA (1)	CA2535071A1 (da)
CL (1)	CL2004002035A1 (da)
CR (1)	CR8233A (da)
DE (1)	DE602004029581D1 (da)
DK (1)	DK1656391T3 (da)
EA (1)	EA200600234A1 (da)
EC (1)	ECSP066359A (da)
ES (1)	ES2351395T3 (da)
GT (1)	GT200400158A (da)
IL (1)	IL173273A (da)
IS (1)	IS8266A (da)
MA (1)	MA27988A1 (da)
MX (1)	MXPA06001634A (da)
NL (1)	NL1026829C2 (da)
NO (1)	NO20060542L (da)
OA (1)	OA13234A (da)
PA (1)	PA8608801A1 (da)
PE (1)	PE20050339A1 (da)
PL (1)	PL1656391T3 (da)
PT (1)	PT1656391E (da)
RS (1)	RS20060099A (da)
TN (1)	TNSN06050A1 (da)
TW (1)	TWI294915B (da)
UA (1)	UA85058C2 (da)
UY (1)	UY28464A1 (da)
WO (1)	WO2005016967A2 (da)
ZA (1)	ZA200601231B (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2433800C (en)	2001-01-05	2016-09-13	Pfizer Inc.	Antibodies to insulin-like growth factor i receptor
PL210412B1 (pl)	2002-05-24	2012-01-31	Schering Corp	Izolowane przeciwciało anty-IGFR lub jego fragment, kompozycja farmaceutyczna, zastosowanie, kwas nukleinowy, zrekombinowany wektor, komórka gospodarza, kompleks, polipeptyd i sposób jego wytwarzania
EP2365001A3 (en) *	2003-05-01	2012-03-28	Imclone LLC	Fully human antibodies directed against the human insulin-like growth factor-1 receptor
PT1656391E (pt) *	2003-08-13	2010-12-06	Pfizer Prod Inc	Anticorpos humanos modificados contra igf-ir
CN1938428A (zh)	2003-11-12	2007-03-28	先灵公司	多基因表达的质粒***
PE20050928A1 (es)	2003-11-21	2005-11-08	Schering Corp	Combinaciones terapeuticas de anticuerpo anti-igfr1
JP2008506681A (ja)	2004-07-16	2008-03-06	ファイザー・プロダクツ・インク	抗ｉｇｆ−１ｒ抗体を用いる非血液性の悪性腫瘍の併用療法
FR2873699B1 (fr) *	2004-07-29	2009-08-21	Pierre Fabre Medicament Sa	Nouveaux anticorps anti igf ir rt leurs utilisations
EP2283831A3 (en)	2004-12-03	2013-10-23	Merck Sharp & Dohme Corp.	Biomakers for pre-selection of patients for anti-IGF1R therapy
MY146381A (en)	2004-12-22	2012-08-15	Amgen Inc	Compositions and methods relating relating to anti-igf-1 receptor antibodies
GB0500417D0 (en) *	2005-01-10	2005-02-16	Cambridge Antibody Tech	Method of mutagenesis
JP4875064B2 (ja) *	2005-04-15	2012-02-15	シェーリングコーポレイション	癌を処置または予防するための方法および組成物
AU2006259536A1 (en) *	2005-06-15	2006-12-28	Schering Corporation	Anti-IGF1R antibody formulations
DK2100618T3 (da)	2005-06-17	2014-03-03	Imclone Llc	Anti-PDGFR-alpha-antistof til anvendelse ved behandling af metastatisk knoglekræft
FR2888850B1 (fr) *	2005-07-22	2013-01-11	Pf Medicament	Nouveaux anticorps anti-igf-ir et leurs applications
WO2007092453A2 (en) *	2006-02-03	2007-08-16	Imclone Systems Incorporated	Igf-ir antagonists as adjuvants for treatment of prostate cancer
RU2008142359A (ru) *	2006-03-28	2010-05-10	Ф.Хоффманн-Ля Рош Аг (Ch)	Композиция человеческого моноклонального антитела к igf-1r
US7846724B2 (en)	2006-04-11	2010-12-07	Hoffmann-La Roche Inc.	Method for selecting CHO cell for production of glycosylated antibodies
KR20140052081A (ko)	2006-06-02	2014-05-02	화이자 프로덕츠 인코포레이티드	순환 종양 세포 분석
TW200833711A (en) *	2006-12-22	2008-08-16	Genentech Inc	Antibodies to insulin-like growth factor receptor
GB0702888D0 (en) *	2007-02-14	2007-03-28	Glaxo Group Ltd	Novel Antibodies
WO2008108986A2 (en) *	2007-03-02	2008-09-12	Amgen Inc.	Methods and compositions for treating tumor diseases
AU2012203443B2 (en) *	2007-03-02	2014-03-06	Amgen Inc.	Methods and compositions for treating tumor diseases
CN101668540A (zh) *	2007-03-22	2010-03-10	英克隆有限责任公司	稳定的抗体制剂
EP2145021A2 (en)	2007-05-17	2010-01-20	Bristol-Myers Squibb Company	Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
ES2388017T3 (es)	2007-12-21	2012-10-05	Roche Glycart Ag	Ensayo de estabilidad de anticuerpos
JP2011515478A (ja) *	2008-03-25	2011-05-19	シェーリングコーポレイション	結腸直腸がんを処置または予防するための方法
EP2282739A2 (en) *	2008-05-05	2011-02-16	Schering Corporation	Sequential administration of chemotherapeutic agents for treatment of cancer
AU2009313389A1 (en) *	2008-11-06	2010-05-14	Alexion Pharmaceuticals, Inc.	Engineered antibodies with reduced immunogenicity and methods of making
EP2400985A2 (en)	2009-02-25	2012-01-04	OSI Pharmaceuticals, LLC	Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
EP2236139A1 (en)	2009-03-31	2010-10-06	F. Hoffmann-La Roche AG	Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
US20100316639A1 (en)	2009-06-16	2010-12-16	Genentech, Inc.	Biomarkers for igf-1r inhibitor therapy
TWI513465B (zh)	2009-06-25	2015-12-21	Regeneron Pharma	以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
BR112012009828B8 (pt)	2009-10-26	2022-10-25	Hoffmann La Roche	Método para a produção de uma imunoglobulina glicosilada e seu uso
WO2011053779A2 (en)	2009-10-30	2011-05-05	Bristol-Myers Squibb Company	Methods for treating cancer in patients having igf-1r inhibitor resistance
AU2014262201B2 (en) *	2009-12-23	2016-09-15	Novartis Ag	Method for decreasing immunogenicity
JP5914353B2 (ja)	2009-12-23	2016-05-11	エスバテック − アノバルティスカンパニーエルエルシー	免疫原性を減少させるための方法
US20110200595A1 (en)	2010-02-18	2011-08-18	Roche Glycart	TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
WO2011161119A1 (en)	2010-06-22	2011-12-29	F. Hoffmann-La Roche Ag	Antibodies against insulin-like growth factor i receptor and uses thereof
AR082205A1 (es)	2010-07-12	2012-11-21	Covx Technologies Ireland Ltd	Conjugados de anticuerpos multifuncionales
US20140037642A1 (en)	2011-02-02	2014-02-06	Amgen Inc.	Methods and compositions relating to inhibition of igf-1r
DK2699598T3 (da)	2011-04-19	2019-04-23	Pfizer	Kombinationer af anti-4-1bb-antistoffer og adcc-inducerende antistoffer til behandling af kræft
US20140309229A1 (en)	2011-10-13	2014-10-16	Bristol-Myers Squibb Company	Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
EP2802355B1 (en) *	2012-01-09	2018-09-05	CovX Technologies Ireland Limited	Mutant antibodies and conjugation thereof
EP2631653A1 (en)	2012-02-24	2013-08-28	Charité - Universitätsmedizin Berlin	Identification of modulators of binding properties of antibodies reactive with a member of the insulin receptor family
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
SG11201502937PA (en) *	2012-11-06	2015-06-29	Medimmune Llc	COMBINATION THERAPIES USING ANTI-<i>PSEUDOMONAS</i> PSL AND PCRV BINDING MOLECULES
TWI747803B (zh)	2013-04-29	2021-12-01	瑞士商赫孚孟拉羅股份公司	人類結合ｆｃｒｎ之經修飾抗體及使用方法
CN103319598B (zh) *	2013-05-13	2014-10-22	杭州德同生物技术有限公司	抗***-1受体抗体及其编码基因和应用
MX2016008782A (es)	2014-01-15	2016-09-08	Hoffmann La Roche	Variantes de region fc con union mejorada de la proteina a.
EP3719040A1 (en) *	2017-07-27	2020-10-07	iTeos Therapeutics SA	Anti-tigit antibodies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6054561A (en)	1984-02-08	2000-04-25	Chiron Corporation	Antigen-binding sites of antibody molecules specific for cancer antigens
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US6657103B1 (en)	1990-01-12	2003-12-02	Abgenix, Inc.	Human antibodies derived from immunized xenomice
GB9203459D0 (en)	1992-02-19	1992-04-08	Scotgen Ltd	Antibodies with germ-line variable regions
US5863949A (en)	1995-03-08	1999-01-26	Pfizer Inc	Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (en)	1995-04-20	2001-07-24	Pfizer Inc.	Arylsulfonyl hydroxamic acid derivatives
ATE390933T1 (de)	1995-04-27	2008-04-15	Amgen Fremont Inc	Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
IL118626A0 (en)	1996-06-11	1996-10-16	Xtl Biopharmaceuticals Limited	Anti HBV antibody
TR199900066T2 (xx)	1996-07-18	1999-04-21	Pfizer Inc.	Matriks metalloproteazlar�n fosfinat bazl� inhibit�rleri
IL128189A0 (en)	1996-08-23	1999-11-30	Pfizer	Arylsulfonylamino hydroxamic acid derivatives
IL139707A0 (en)	1998-05-15	2002-02-10	Imclone Systems Inc	Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
EE05627B1 (et) *	1998-12-23	2013-02-15	Pfizer Inc.	CTLA-4 vastased inimese monoklonaalsed antikehad
CA2796140A1 (en)	1999-03-25	2000-09-28	Jochen Salfeld	Human antibodies that bind human il-12 and methods for producing
ES1042735Y (es)	1999-04-07	2000-02-16	Martinez Fernando Martinez	Vehiculo tripersonal de accionamiento a pedales.
US20030165502A1 (en)	2000-06-13	2003-09-04	City Of Hope	Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
DE10033869C2 (de)	2000-07-12	2003-07-31	Karlsruhe Forschzent	HTS-Kryomagnet und Aufmagnetisierungsverfahren
CA2433800C (en) *	2001-01-05	2016-09-13	Pfizer Inc.	Antibodies to insulin-like growth factor i receptor
WO2002066058A1 (en)	2001-02-19	2002-08-29	Merck Patent Gmbh	Modified anti-egfr antibodies with reduced immunogenicity
EP1798242B1 (fr)	2002-01-18	2013-01-23	Pierre Fabre Medicament	Anticorps anti-IGF-IR et leurs applications
AU2003231554A1 (en)	2002-04-30	2003-11-17	Kyowa Hakko Kogyo Co., Ltd.	Antibody to human insulin-like growth factor
PL210412B1 (pl)	2002-05-24	2012-01-31	Schering Corp	Izolowane przeciwciało anty-IGFR lub jego fragment, kompozycja farmaceutyczna, zastosowanie, kwas nukleinowy, zrekombinowany wektor, komórka gospodarza, kompleks, polipeptyd i sposób jego wytwarzania
GB0212303D0 (en)	2002-05-28	2002-07-10	Isis Innovation	Molecular targetting of IGF-1 receptor
US7538195B2 (en)	2002-06-14	2009-05-26	Immunogen Inc.	Anti-IGF-I receptor antibody
NZ582210A (en)	2003-02-13	2011-04-29	Pfizer Prod Inc	Uses of anti-insulin-like growth factor I receptor antibodies
MXPA05009837A (es)	2003-03-14	2005-12-05	Pharmacia Corp	Anticuerpos para el receptor del factor de crecimiento tipo insulina-i, para el tratamiento de canceres.
CA2519113C (en)	2003-04-02	2012-06-05	F. Hoffmann-La Roche Ag	Antibodies against insulin-like growth factor i receptor and uses thereof
PT1656391E (pt) *	2003-08-13	2010-12-06	Pfizer Prod Inc	Anticorpos humanos modificados contra igf-ir

2004
- 2004-08-03 PT PT04744197T patent/PT1656391E/pt unknown
- 2004-08-03 CA CA002535071A patent/CA2535071A1/en not_active Abandoned
- 2004-08-03 JP JP2006523070A patent/JP4638870B2/ja not_active Expired - Fee Related
- 2004-08-03 RS YUP-2006/0099A patent/RS20060099A/sr unknown
- 2004-08-03 KR KR1020067002957A patent/KR100825156B1/ko not_active IP Right Cessation
- 2004-08-03 ES ES04744197T patent/ES2351395T3/es active Active
- 2004-08-03 DE DE602004029581T patent/DE602004029581D1/de active Active
- 2004-08-03 EA EA200600234A patent/EA200600234A1/ru unknown
- 2004-08-03 AT AT04744197T patent/ATE484525T1/de active
- 2004-08-03 EP EP04744197A patent/EP1656391B1/en active Active
- 2004-08-03 MX MXPA06001634A patent/MXPA06001634A/es unknown
- 2004-08-03 CN CN2004800230991A patent/CN1835975B/zh not_active Expired - Fee Related
- 2004-08-03 AU AU2004265152A patent/AU2004265152A1/en not_active Abandoned
- 2004-08-03 WO PCT/IB2004/002555 patent/WO2005016967A2/en active Application Filing
- 2004-08-03 BR BRPI0413466-4A patent/BRPI0413466A/pt not_active IP Right Cessation
- 2004-08-03 OA OA1200600046A patent/OA13234A/en unknown
- 2004-08-03 AP AP2006003510A patent/AP2006003510A0/xx unknown
- 2004-08-03 PL PL04744197T patent/PL1656391T3/pl unknown
- 2004-08-03 DK DK04744197.7T patent/DK1656391T3/da active
- 2004-08-03 UA UAA200601349A patent/UA85058C2/ru unknown
- 2004-08-09 PE PE2004000773A patent/PE20050339A1/es not_active Application Discontinuation
- 2004-08-10 CL CL200402035A patent/CL2004002035A1/es unknown
- 2004-08-11 UY UY28464A patent/UY28464A1/es not_active Application Discontinuation
- 2004-08-11 AR ARP040102870A patent/AR045247A1/es active IP Right Grant
- 2004-08-12 TW TW093124269A patent/TWI294915B/zh not_active IP Right Cessation
- 2004-08-12 US US10/917,073 patent/US7371378B2/en not_active Expired - Fee Related
- 2004-08-12 GT GT200400158A patent/GT200400158A/es unknown
- 2004-08-12 PA PA20048608801A patent/PA8608801A1/es unknown
- 2004-08-12 NL NL1026829A patent/NL1026829C2/nl not_active IP Right Cessation
2006
- 2006-01-19 IL IL173273A patent/IL173273A/en not_active IP Right Cessation
- 2006-01-26 IS IS8266A patent/IS8266A/is unknown
- 2006-02-02 NO NO20060542A patent/NO20060542L/no not_active Application Discontinuation
- 2006-02-10 EC EC2006006359A patent/ECSP066359A/es unknown
- 2006-02-10 ZA ZA200601231A patent/ZA200601231B/en unknown
- 2006-02-13 TN TNP2006000050A patent/TNSN06050A1/fr unknown
- 2006-02-13 CR CR8233A patent/CR8233A/es not_active Application Discontinuation
- 2006-02-13 MA MA28790A patent/MA27988A1/fr unknown
2008
- 2008-03-03 US US12/041,341 patent/US7575746B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1656391B1 (en)	2010-10-13
PT1656391E (pt)	2010-12-06
MXPA06001634A (es)	2006-04-28
NO20060542L (no)	2006-05-03
PA8608801A1 (es)	2005-03-03
UA85058C2 (ru)	2008-12-25
UY28464A1 (es)	2005-03-31
ATE484525T1 (de)	2010-10-15
US20080181891A1 (en)	2008-07-31
OA13234A (en)	2006-12-13
JP4638870B2 (ja)	2011-02-23
NL1026829A1 (nl)	2005-02-15
US20050069539A1 (en)	2005-03-31
CL2004002035A1 (es)	2005-06-03
CN1835975A (zh)	2006-09-20
US7371378B2 (en)	2008-05-13
WO2005016967A3 (en)	2005-04-14
TW200516145A (en)	2005-05-16
AU2004265152A1 (en)	2005-02-24
ES2351395T3 (es)	2011-02-04
TNSN06050A1 (fr)	2007-10-03
TWI294915B (en)	2008-03-21
CR8233A (es)	2007-01-18
BRPI0413466A (pt)	2006-10-17
US7575746B2 (en)	2009-08-18
EP1656391A2 (en)	2006-05-17
ECSP066359A (es)	2006-10-31
RS20060099A (en)	2008-08-07
IL173273A (en)	2011-10-31
IL173273A0 (en)	2006-06-11
KR20060035796A (ko)	2006-04-26
CA2535071A1 (en)	2005-02-24
PL1656391T3 (pl)	2011-03-31
EA200600234A1 (ru)	2006-08-25
MA27988A1 (fr)	2006-07-03
CN1835975B (zh)	2012-11-21
WO2005016967A2 (en)	2005-02-24
GT200400158A (es)	2005-07-22
DE602004029581D1 (de)	2010-11-25
KR100825156B1 (ko)	2008-04-24
AR045247A1 (es)	2005-10-19
ZA200601231B (en)	2007-05-30
IS8266A (is)	2006-01-26
AP2006003510A0 (en)	2006-02-28
NL1026829C2 (nl)	2005-07-05
PE20050339A1 (es)	2005-05-17
JP2007527705A (ja)	2007-10-04

Publication	Publication Date	Title
DK1656391T3 (da)	2011-01-03	Modificerede humane IGF-1R antistoffer
ATE465180T1 (de)	2010-05-15	Therapeutische anti-igfr1-antikörper- kombinationen
DK1844074T3 (da)	2013-07-15	Humane antistoffer og proteiner
CY2016035I1 (el)	2017-09-13	Θεραπευτικη χρηση αντισωματων anti-cs1
CY2016016I2 (el)	2016-12-14	Ανθρωπινο αντισωμα αντι-υποδοχεα επιδερμικου αυξητικου παραγοντα
DK1599504T3 (da)	2015-03-09	Modificeret antistof
NO20071430L (no)	2007-05-15	Anti-OX4OL antistoffer
DK1432735T3 (da)	2012-08-06	Antagonistiske humane anti-htnfsf13b-antistoffer
NO20052889D0 (no)	2005-06-14	Humane monoklonale antistoffer mot CD25
ATE440867T1 (de)	2009-09-15	Interleukin-10-antikírper
NO20044347L (no)	2004-12-13	Anti-alfavbeta6-antistoff
IS3021B (is)	2020-04-15	Mótefni gegn M-CSF
IS7668A (is)	2005-01-27	Manngerð mótefni gegn 4-1BB í mönnum
CY2012019I2 (el)	2015-08-05	Ανθρωπινα μονοκλωνα αντισωματα εναντια στο cd20
DK1737891T3 (da)	2013-03-25	Anti-p-selectin-antistoffer
ATE480567T1 (de)	2010-09-15	Hochkonzentrierter antikörper und proteinformulierungen
DK1817343T3 (da)	2014-09-15	Humane monoklone antistoffer mod humant IL-4
ATE396612T1 (de)	2008-06-15	Schleppnetz
IL172511A0 (en)	2006-04-10	Specific human antibodies
DE60336777D1 (de)	2011-05-26	Responder
DE502004009935D1 (de)	2009-10-01	Substituierte dihydrochinazoline ii
DE602004016637D1 (de)	2008-10-30	Abferkelstation
SI1656391T1 (sl)	2010-12-31	Modificirana humana IGF-1R protitelesa
DE60238559D1 (de)	2011-01-20	Criptospezifische antikörper
PT9865T (pt)	2003-06-30	Asa rotulo